I will:
“The first thing I started to
notice as my walking improved with
Ampyra was my confidence in my ability
to walk to meet my friends.”
— Kristie Salerno Kent,
diagnosed with MS in 1999.
Walk on.
Walking better matters. AMPYRA
is the first and only medication
shown in two clinical trials to
improve walking in people with
multiple sclerosis (MS).
This was demonstrated by an
increase in walking speed.
In these clinical studies, people who
walked faster, regardless of treatment,
reported improvements in their
walking related activities.
Not everyone responds to AMPYRA.
Individual results may vary.
Can be taken in combination
with your other MS therapies.
Visit Ampyra.com to find out
more about a FREE TRIAL.
Talk to your doctor to see if AMPYRA may be right
for you.
New Safety Information
Ampyra may cause serious allergic reactions,
including rare occurrences of anaphylaxis.
Important Safety Information
Do not take AMPYRA if you have ever had a seizure
or have certain types of kidney problems.
Take AMPYRA exactly as prescribed by your doctor.
You could have a seizure even if you never had a
seizure before. Your chance of having a seizure is
higher if you take too much AMPYRA or if your
kidneys have a mild decrease of function, which is
common after age 50. Your doctor may do a blood
test to check how well your kidneys are working, if
that is not known before you start taking AMPYRA.
In two pivotal trials 35% and 43% of patients taking
AMPYRA responded to treatment vs. 8% and 9% of
patients taking placebo.
AMPYRA® is a registered trademark of Acorda
Therapeutics®, Inc. AMPYRA is marketed by Acorda
Therapeutics, Inc. and is manufactured under license
from Alkermes Pharma Ireland Ltd. © 2012 Acorda
Therapeutics, Inc. All Rights Reserved. 09/12 AMP2049
AMPYRA should not be taken with other forms of
4-aminopyridine (4-AP, fampridine), since the active
ingredient is the same.
For more information, please see the complete
Medication Guide on the next page.
You are encouraged to report negative side effects of
prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
